2,3,7,8-Tetrachlorodibenzo-p-dioxin

CAS RN: 1746-01-6

Treatment Overview

0.4.2 ORAL EXPOSURE
  • A) MANAGEMENT OF TOXICITY
    • 1) Treatment is symptomatic and supportive following acute exposure.
    • 2) CHLORACNE: Generally resistant to modes of therapy used for acne vulgaris. Acne surgery and dermabrasion have been most beneficial. Topical retinoic acid 0.05% to 0.3% for up to 10 months may be useful. Tetracyclines may be used to treat secondary pustular follicles.
    • 3) BRONCHOSPASM: 100% humidified supplemental oxygen, perform endotracheal intubation and assisted ventilation as required. Beta adrenergic agonists as needed.
  • B) DECONTAMINATION
    • 1) DERMAL: Remove contaminated clothing and wash exposed area extremely thoroughly with soap and water. Personnel involved in washing patients should wear gloves and avoid contact with contaminated clothing.
    • 2) OCULAR: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persists after 15 minutes of irrigation, and ophthalmologic examination should be performed.
    • 3) ORAL: Gastric lavage: Consider it in the unlikely case of severe acute ingestions if it can be performed soon after ingestion. Activated charcoal: Most exposures are chronic and routine gastrointestinal decontamination is not indicated. In the unlikely event of acute ingestion, administer activated charcoal if conditions are appropriate.
  • C) AIRWAY MANAGEMENT
    • 1) Endotracheal intubation should be performed in patients with excessive drowsiness and the inability to protect their own airway.
  • D) ANTIDOTE
    • 1) None.
  • E) ENHANCED ELIMINATION
    • 1) Elimination may be enhanced through administration of olestra by increasing fecal excretion.
  • F) PATIENT DISPOSITION
    • 1) OBSERVATION CRITERIA: Patients should be observed in a medical facility until free of acute symptoms. Carefully observe patients with inhalation exposure for the development of any systemic signs or symptoms and administer symptomatic treatment as necessary.
    • 2) ADMISSION CRITERIA: All patients who are acutely symptomatic should be admitted for observation.
    • 3) CONSULT CRITERIA: Consult a medical toxicologist for assistance with any acute exposure or if the diagnosis is unclear.
  • G) PHARMACOKINETICS
    • 1) Bioavailability is generally unknown and gastrointestinal absorption varies with the vehicle used. Dioxins are lipophilic, found mostly in adipose tissue, skin, liver pancreas and breast milk. TCDD is absorbed by the lymphatic system and is transported by chylomicrons and lipoproteins. Dioxins and TCDD are hepatically metabolized, by cytochrome P450. Excretion is largely fecal. Half-life of TCDD is 5 to 11 years.
Find more information on this substance at: PubChem, PubMed